Nonpharmacological harm-reduction interventions in British substance-misuse services

Rosenberg, Harold; Melville, Joel G̀.; McLean, P. C.

doi:10.1016/j.addbeh.2004.03.021

Cited by 6 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, those who consume ecstasy less frequently may not see themselves as being at risk for harmful consequences and therefore may employ harm reduction strategies less often compared to those who consume the substance more frequently. In addition, the proportion of users who employ these strategies could vary by country as a result of widespread professional (and perhaps non-professional) acceptance of harm reduction in the United Kingdom (Rosenberg et al., 2002, 2004) compared to the United States (Rosenberg and Davis, 2014; Rosenberg and Phillips, 2003). Therefore, to evaluate whether frequency of ecstasy consumption (higher or lower) and country of residence (US or UK) were associated with use of ecstasy-specific harm reduction strategies, we compared the proportions of American and British higher-frequency and lower-frequency ecstasy users who had employed each of 19 strategies when they used ecstasy during a 2-month period.…”

Section: Introductionmentioning

confidence: 99%

Specific harm reduction strategies employed by 3,4-methylenedioxymethamphetmine/ ecstasy users in the United States and the United Kingdom

Davis

Rosenberg

2017

Drug Science, Policy and Law

Self Cite

View full text Add to dashboard Cite

Both recreational and problematic MDMA/ecstasy users could benefit from employing harm reduction interventions intended to preserve health and prevent negative consequences. To evaluate whether use of such interventions varied by country of residence and frequency of ecstasy use, we used web-based surveys to assess how often 104 lower-frequency and higher-frequency American ecstasy users and 80 lower-frequency and higher-frequency British ecstasy users employed each of 19 self-initiated harm reduction strategies when they used ecstasy during a two-month period. Several significant differences notwithstanding, at least 75% of participants had used 11 of the 19 strategies one or more times during the two-month assessment period, regardless of whether they lived in the United States or United Kingdom and whether they were lower-frequency or higher-frequency ecstasy users. When proportions of American and British participants using a strategy differed significantly, it was typically larger proportions of Americans using those strategies. Many of the less frequently employed strategies are not applicable on every occasion of ecstasy use. However, because ecstasy is not a diverted pharmaceutical of known quality/potency, testing for the presence of MDMA, other stimulants, and adulterants is a strategy that everyone should employ, regardless of country of residence or how frequently one consumes ecstasy.

show abstract

Section: Introductionmentioning

confidence: 99%

Specific harm reduction strategies employed by 3,4-methylenedioxymethamphetmine/ ecstasy users in the United States and the United Kingdom

Davis

Rosenberg

2017

Drug Science, Policy and Law

Self Cite

View full text Add to dashboard Cite

show abstract

“…It has been estimated that up to 45% of substance users employ natural and complementary therapies [1]; surveys suggest that more than three-quarters of substance users contacting treatment services find complementary or alternative treatments acceptable [2,3].…”

Section: Introductionmentioning

confidence: 99%

Natural and complementary therapies for substance use disorders

Dean

2005

Current Opinion in Psychiatry

View full text Add to dashboard Cite

Several pharmacological and psychosocial treatments for substance use disorders are solidly evidence-based and improve both individual and public health outcomes. At this stage, there remains insufficient evidence to support the use of natural and complementary therapies as a primary intervention for substance use disorders. Further clinical trials are required to clarify the potential role of particular agents.

show abstract

High and low threshold service provision in drug-free settings: Practitioner views

Eversman

2010

International Journal of Drug Policy

View full text Add to dashboard Cite

Nonpharmacological harm-reduction interventions in British substance-misuse services

Cited by 6 publications

References 7 publications

Specific harm reduction strategies employed by 3,4-methylenedioxymethamphetmine/ ecstasy users in the United States and the United Kingdom

Specific harm reduction strategies employed by 3,4-methylenedioxymethamphetmine/ ecstasy users in the United States and the United Kingdom

Natural and complementary therapies for substance use disorders

High and low threshold service provision in drug-free settings: Practitioner views

Contact Info

Product

Resources

About